- Home
- NVAX vs CNCK Comparison
NVAX vs CNCK Comparison
Compare NVAX & CNCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- CNCK
- Stock Information
- Founded
- NVAX 1987
- CNCK 2012
- Country
- NVAX United States
- CNCK Netherlands
- Employees
- NVAX N/A
- CNCK N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CNCK
- Sector
- NVAX Health Care
- CNCK
- Exchange
- NVAX Nasdaq
- CNCK NYSE
- Market Cap
- NVAX 1.3B
- CNCK N/A
- IPO Year
- NVAX 1995
- CNCK N/A
- Fundamental
- Price
- NVAX $6.66
- CNCK $7.80
- Analyst Decision
- NVAX Buy
- CNCK Buy
- Analyst Count
- NVAX 6
- CNCK 1
- Target Price
- NVAX $17.83
- CNCK $10.00
- AVG Volume (30 Days)
- NVAX 8.5M
- CNCK 48.5K
- Earning Date
- NVAX 05-08-2025
- CNCK 05-13-2025
- Dividend Yield
- NVAX N/A
- CNCK N/A
- EPS Growth
- NVAX N/A
- CNCK N/A
- EPS
- NVAX 2.97
- CNCK N/A
- Revenue
- NVAX $1,254,962,000.00
- CNCK $2,354,350,618.00
- Revenue This Year
- NVAX N/A
- CNCK N/A
- Revenue Next Year
- NVAX N/A
- CNCK N/A
- P/E Ratio
- NVAX $2.24
- CNCK N/A
- Revenue Growth
- NVAX 25.92
- CNCK 57.02
- 52 Week Low
- NVAX $4.43
- CNCK $4.22
- 52 Week High
- NVAX $23.86
- CNCK $14.99
- Technical
- Relative Strength Index (RSI)
- NVAX 51.25
- CNCK N/A
- Support Level
- NVAX $5.82
- CNCK N/A
- Resistance Level
- NVAX $6.61
- CNCK N/A
- Average True Range (ATR)
- NVAX 0.53
- CNCK 0.00
- MACD
- NVAX 0.02
- CNCK 0.00
- Stochastic Oscillator
- NVAX 42.21
- CNCK 0.00
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.